DUBLIN, October 25, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Humira Biosimilars Clinical Trial Insight" clinical trials to their offering.
The Humira Biosimilars Clinical Trial Insight report gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
The Humira stands for Human Monoclonal Antibody in Rheumatoid Arthritis. It is also termed as Adalimumab or D2E7 and is a recombinant Immunoglobulin G1 monoclonal antibody which is specific for tumor necrosis factor alpha (TNF-a). It is a drug designed by the mode of recombinant DNA technology for the treatment of rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In the rheumatoid arthritis adalimumab has the equivalent efficacy as that of methotrexate.
It is produced by Abbot Laboratories but originally Humira was emerged from collaboration between Bioresearch Center in Massachusetts (BASF) and the Cambridge Antibody Technologies in the UK. Mid stage clinical trials were so promising that, at the end of 2000, Abbott agreed to buy the BASF Bioresearch Center for US$ 6.9 Billion. When Humira was launched in 2003, it was the third TNF-alpha antibody to the market. Its US, FDA approval for marketing was achieved on December 31, 2002. In 2012 to 2015 Humira topped the top selling pharmaceutical product lists and in 2015, Humira had topped US$ 14 Billion of sales globally.
However, its superior dosing schedule and improved toleration over existing therapy enabled it to become the best in class agent. Furthermore, Abbott had a robust development program for Humira and expanded its use to other inflammatory disease such as psoriasis, Crohn's disease, and juvenile idiopathic arthritis. While prescribed to far fewer patients than Lipitor, the high cost of this biological medicine is such that Humira's sales were projected to exceed US$ 9 Billion.
In December 2014, Indian drug maker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its U.S. price. The generic has been launched under the brand name Exemptia. In January 2016, another Indian drug maker Torrent Pharmaceuticals launched its biosimilar for adalimumab. Torrent's Adfrar would be the second generic biosimilar of adalimumab in the world. In September 2016 the US FDA approved Amgens biosimilar adalimumab-atto sold under the brand name Amjevita.
Humira (Adalimumab) Clinical Insight
- Clinical Introduction
- Company Partnerships & Agreements
- Patent Analysis by Indication
- Designated Orphan Status by Indication & Country
- Brand Names by Country/Region
Humira Biosimilars Clinical Insight by Company
- AET BioTech/BioXpress Therapeutics
- BIOCND/Genor Biopharma
- Bionovis/The Instituto Vital Brazil
- Boehringer Ingelheim
- Coherus BioSciences
- Dong A ST/Meiji Seika Pharma
- EMD Serono/Merck
- Fujifilm Kyowa Kirin Biologics
- Gene Techno Science
- Harvest Moon Pharmaceuticals
- Hetero Drugs
- Innovent Biologics
- LG Life Sciences
- Meridian Biopharmaceuticals
- Momenta Pharmaceuticals
- Reliance Life Sciences
- Samsung Bioepis
- Shanghai Henlius Biotech
- Therapeutic Proteins International
- Zydus Cadila
For more information about this clinical trials report visit http://www.researchandmarkets.com/research/6qbqrp/humira
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets